Cue Biopharma
Develops immune-modulating biologics for autoimmune and allergic diseases.
$27.88
After-hours close−0.30 (−1.06%)
At close$28.18(+0.07%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 62.46%1.64M sharesInsiders 25.86%679.5K sharesOther 11.68%306.9K shares
Shares outstanding 2.63M · Float —
Float — provider float is below the insider stake.
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Institutions13F, as of Jun 30, 2026
51 holders · 1.64M shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bleichroeder LP | 370.7K | 14.11% | Aug 13, 2026 | |
| Driehaus Capital Management LLC | 292.1K | 11.12% | Aug 14, 2026 | |
| Vanguard Capital Management LLC | 161.7K | 6.15% | Aug 13, 2026 | |
| Ikarian Capital, LLC | 104.4K | 3.97% | Aug 14, 2026 | |
| TFG Asset Management GP Ltd | 93.8K | 3.57% | Aug 13, 2026 | |
| Stempoint Capital LP | 67.0K | 2.55% | Aug 14, 2026 | |
| BlackRock, Inc. | 57.8K | 2.20% | Aug 7, 2026 | |
| Adar1 Capital Management, LLC | 55.2K | 2.10% | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Bleichroeder LP | 9.99% | 13G | Mar 21, 2025 ↗ | |
| Driehaus Capital Management LLC | 6.96% | 292.1K | 13G | Aug 14, 2026 ↗ |
| Shao-Lee Lin | 6.20% | 467.2K | 13D | Aug 21, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Shao-Lee Lin | director, officer: Chief Executive Officer | 467.2K | 17.78% | Aug 14, 2026 |
| Sumita Ray | officer, other: Chief Legal Compliance Officer | 36.4K | 1.38% | Aug 17, 2026 |
| Dominique Christian Borie | officer, other: Chief Medical Officer | 31.5K | 1.20% | Jul 15, 2026 |
| Pasha Sarraf | director | 29.2K | 1.11% | Aug 28, 2026 |
| Michael Vincent Meluzio | officer: VP, Prin. Accounting Officer | 27.3K | 1.04% | Aug 17, 2026 |
| James M. Ahlers | officer: Chief Financial Officer | 25.5K | 0.97% | Aug 3, 2026 |
| Daniel A. Camardo | director | 21.8K | 0.83% | Jul 10, 2026 |
| Viola Mong Meehan | director | 21.8K | 0.83% | Jul 10, 2026 |
| Pamela Garzone | director | 18.9K | 0.72% | Aug 28, 2026 |
16 people have not refiled in the last 18 months (131.3K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 13, 2026 | Michael Vincent Meluzioofficer: VP, Prin. Accounting Officer | Sale · 3 lots | 5,628 | $30.09 | 48,961 |
| Aug 13, 2026 | Sumita Rayofficer, other: Chief Legal Compliance Officer | Sale · 3 lots | 8,829 | $30.09 | 118,545 |
| Aug 13, 2026 | Shao-Lee Lindirector, officer: Chief Executive Officer | Sale · 3 lots | 18,258 | $28.62 | 705,995 |
| Aug 12, 2026 | Shao-Lee Lindirector, officer: Chief Executive Officer | Sale · 2 lots | 40,000 | $27.10 | 724,253 |
| Jun 1, 2026 | Shao-Lee Lindirector, officer: Chief Executive Officer | Purchase · 2 lots | 136,359 | $3.67 | 136,359 |
| Dec 30, 2025 | Pasha Sarrafdirector | Purchase · 5 lots | 323,857 | $0.3080 | 323,857 |
CongressHouse and Senate disclosures
Not reported.